150 likes | 285 Vues
PRoBaND Parkinson ’ s Repository of Biosamples and Networked Datasets. History Hypotheses Overview Linkage to other studies. Dr Donald Grosset Consultant Neurologist Institute of Neurological Sciences Glasgow. Funded by Parkinson ’ s UK. PRoBAND: history.
E N D
PRoBaNDParkinson’s Repository of Biosamples and Networked Datasets History Hypotheses Overview Linkage to other studies Dr Donald Grosset Consultant Neurologist Institute of Neurological Sciences Glasgow Funded by Parkinson’s UK
PRoBAND: history Parkinson’s UK places call for major biomarker study Joint scientific and clinical consortia form PRoBaND is the clinical consortium to 2 of 3 studies Discovery Award goes to Oxford group Parkinson’s UK seeks reactivation of PRoBaND PRoBaND funded by Parkinson’s UK
PRoBaND: overview • Prospective clinical study of PD patients and relatives • DNA collected and stored • Serum collected and stored
PRoBaND: concepts Genetic and biomarker diversity explains the varied clinical phenotype of PD Understanding these mechanisms will improve the design and interpretation of basic science and clinical therapeutic studies Large sample sizes are needed to test subsets of PD patients characterised by particular clinical (or genetic, or biomarker) features
PRoBaND: sample size Patients Recent onset PD Diagnosis under 50 2000 240 Gene tests 100 + 1900 – 12 + 228 –
PRoBaND: sample size Patients Recent onset PD Diagnosis under 50 2000 240 Gene tests 100 + 1900 – 12 + 228 – 150 600 750 Siblings
PRoBaND: sample size Patients Recent onset PD Diagnosis under 50 2000 240 Gene tests 100 + 1900 – 12 + 228 – 150 600 18 72 750 90 Siblings
PRoBaND: recruitment of PD cases 35 centres x (average of) 32 cases x 2 years Around 2200 cases (PD diagnosed within last 3 years or <50 years) Study visits 6-monthly for 3 years (recent onset) Only 0 and 6 months for young onset Blood sample for DNA tests and biomarker analysis Clinical scoring: motor, non-motor, olfactory
Clinical measurements: patients • Patient scoring • UPDRS – patient • *Smell – UPSIT • Depression – HADS • Sleep – ESS, RBD, PDSS • Autonomic – SCOPA • QoL – EQ5D, PDQ39 • ICDs – QUIP • NMS scoring • Wearing-off • Clinician scoring • *Past, social and family history • UPDRS - clinician • Cognitive – MoCA, fluency • *Response to medication • Diagnostic evolution *Once during study
PRoBaND: recruitment of siblings 25 centres x (average of) 16 cases x 2 years Around 800 subjects (sibs of PD cases recruited to main study) Visit schedule: 0, 36 months Blood sample for DNA tests and biomarker analysis Health questionnaires and clinical examination
PRoBaND biosamples • Blood for DNA (baseline only) • Serum for biomarkers (every 18 months) • CSF, skin NOT part of the PRoBaND protocol • Consent for future contact included • Parkinson’s UK Tissue Bank enrolment
PRoBaNDBasic plan for Parkinson gene tests LRRK2 GBA Recent onset PD Diagnosis under 50 Parkin (PARK 2) PINK-1 (PARK 6)
PRoBaNDBasic plan for Parkinson gene tests LRRK2 GBA Recent onset PD Diagnosis under 50 Parkin (PARK 2) PINK-1 (PARK 6) Extend to new techniques eg. immunochip analysis
Project linkage: the ‘Networked Datasets’ component of PRoBAND Oxford PD Discovery grant Queens Square PD MRC study (Clinical component) GWAS and young-onset PD gene studies NMS Long (NILS) Study Parkinson’s UK Tissue Bank, Imperial Further studies: eg. MRI for diagnosis / progression
Thanks to… • Study centre principal investigators, PD nurse specialists and teams • Parkinson’s UK • Glasgow BioMedicine • PRoBaND Committee members • National and international collaborators, advisors • DeNDRoN research network